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Abstract
Background: Both benign prostatic hyperplasia (BPH) and Type-1 diabetes mellitus (T1DM) share similar
epidemiologic features and are all associated with the insulin-like growth factor (IGF)-mediated hormonal
imbalance. The purpose of this study is to understand whether exercise (EX) could alleviate DM and DM+ BPH.
Methods: Sprague-Dawley rats were divided into eight groups: normal control, EX, BPH, BPH + EX, DM, DM+ EX,
BPH + DM, and BPH + DM+ EX. T1DM was induced by intraperitoneal (ip) injection of streptozotocin (65 mg/kg) in
Week 2, and BPH was induced by successive ip injections of Sustanon® (testosterone, 3.5 mg/head) plus estradiol
(0.1 mg/head) from Week 3 to Week 9. Treadmill exercise training (20 m/min, 60 min per time) was performed three
times per week for 6 weeks.
Results: In BPH + EX, EX maintained at a constant body weight (BW); and suppressed stromal layer thickening, collagen
deposition, blood glucose (BG), levels of testosterone (Ts), 5α-reductase(5αRd), dihydrotestosterone (DHT), androgen
receptor (AR), serum hydrogen peroxide, TBARs, and interleukin-6 (IL-6). EX recovered testes size and substantially
increased nitric oxide (NO) levels. In DM + EX group, EX decreased BW, PW, nuclear proliferation, inflammatory cell
aggregation, collagen deposition, and BG. As contrast, EX upregulated insulin, IGF, Ts, NO, 5αRd, AR, and DHT, and
substantially reduced PSA. In BPH + DM + EX, EX maintained BW at a subnormal level, slightly suppressed prostate
stromal inflammation, collagen deposition, and BG, moderately restored sIn and IGF. Although failed to suppress
Ts, EX highly upregulated 5αRd and suppressed DHT and AR, together with highly upregulated NO resulting in
substantially reduced PSA.
Conclusion: EX, by remodeling androgen and NO expressions, can effectively alleviate BPH, DM, and BPH + DM.
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Background
Benign prostatic hyperplasia (BPH) is the most com-
mon benign tumor in men. Epidemiological data have
indicated that BPH may be associated with the meta-
bolic syndrome (MetS) [1] which can substantially in-
crease the risk of BPH and low urinary tract symptoms
(LUTS) [2].
When complicated with diabetes mellitus (DM), the
mechanisms that regulate reactive stroma biology in
BPH can be altered anatomically, pathologically, and
biochemically [3]. Prostatic volume and the anterior-
posterior diameter are positively associated with the
component number of MetS [1]. The possible patho-
physiologic mechanisms needed to explain these rela-
tions include an increased sympathetic tone, the
alterations in sex steroid hormone expression, and the
induction of systemic inflammation and oxidative stress
[4]. The levels of insulin-like growth factor (IGF) and
IGF-binding proteins (IGFBPs) in prostate tissue and
blood are associated with the risk of developing BPH,
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which also regulate the circulating androgen and growth
hormones [2].
Regular exercise (EX) is associated with low levels of
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α),
and simultaneously, with increases in antiinflammatory
substances, such as adiponectin, IL-4, and IL-10 [5].
Hence, moderate EX training can exert antioxidant and
antiinflammatory systemic protective effects [5]. Much
of the literature supports a clinically relevant, independ-
ent, and strong inverse relationship between EX and the
development of BPH and LUTS [6–8]. Furthermore,
running considerable distances per week may lower the
BPH risk, independent of the BMI and diet [9].
EX has been shown to have beneficially improved the
Type 2 DM (T2DM) [10, 11] and BPH [9]. Moreover,
amounting evidences also have revealed that a close as-
sociation between BPH and T2DM through a common
pathogenic mechanism is possible [12]. Parsons et al. in
a chort report indicated that obesity, elevated fasting
plasma glucose level, and DM are risk factors for BPH
[13]. Previous document even substantially pointed out
that diabetic vascular damage may cause hypoxia which
in turn may contribute to pathogenesis of BPH [14].
Recently, we have showed EX beneficially alleviated
BPH [7], however, the documented effect of EX on pa-
tients concomitantly affiliated with BPH plus Type 1
DM (BPH + T1DM) is still lacking. We hypothesized
that EX could be beneficial to BHP + T1DM subjects.
In this present study we developed a BPH + DM rat




T-Pro Western Blot Stripping Reagent was obtained
from BioPioneer (San Diego, CA, USA); streptozotocin
(STZ), Sirius Red, bovine serum albumin (BSA), and so-
dium dodecyl sulfate-polyacrylamide were purchased
from Sigma-Aldrich (St. Louis, MO, USA); Coomassie
Brillant Blue R-250, Coomassie Brilliant Blue-G, glycine,
and Tris base were obtained from US Biological (USA).
Bis-acrylamide solution was purchased from Serva
(Germany). Sustanon® was provided by the Schering-
Plough Company (Kenilworth, NJ, USA) which is an in-
jectable testosterone medication containing four testoster-
one esters at concentrations: 30 mg/mL of testosterone
propionate, 60 mg/mL of testosterone phenylpropio-
nate, 60 mg/mL of testosterone isocaproate, and
100 mg/mL of testosterone decanoate. The overall an-
drogenic potency per mL of Sustanon® is equivalent to
176 mg of testosterone. Tris (hydroxymethyl) amino-
methane hydrochloride (Tris-HCl) and hydrogen per-
oxide were purchased from Panreac (Spain). PageRuler™
Prestained Protein Ladder was supplied by Fermentas
(Canada). TEMED, ammonium persulfate (APS), and
mineral oil were products of Bio-Rad (USA).
The sources of various kits were: Rat insulin ELISA kit
(Mercodia, Sweden), AssayMax mouse insulin-like
growth factor-1 (IGF-1 ELISA Kit; AssayPro, USA), rat
Interleukin-6 (IL-6) ELISA kit (PeproTech, USA).
TBARS ELISA kit (Cayman Chemical, USA), hydrogen
peroxide (H2O2) assay kit (BioVision, USA) testosterone
EIA (Cayman Chemical, USA), and dihydrotestosterone
ELISA kit (Alpha Diagnostic, USA).
While the suppliers of antibodies were: antirabbit IgG
(eBioscience, USA), antimouse IgG (Jackson ImmunoRe-
search, USA), β-actin antibody (Novus Biologicals,
USA), antigoat IgG, 5α-reductase antibody, androgen re-
ceptor antibody (Santa Cruz Co., USA), and prostatic-
specific antigen (PSA) antibody (Bioss, Scotland).
Animals
This experiment was approved by the Institutional
Animal Care and Ethics Committee of Taipei Medical
University (Taipei, Taiwan), and adhered to the animal
care standards of the American College of Sports Medi-
cine. In brief, 64 male Sprague-Dawley rats, aged
6 weeks, weighing 250–265 g were purchased from
Biolasco Co. (Taipei, Taiwan). The rats were housed in
an animal room conditioned at 24 ± 2 °C, RH 70–75 %,
with a 12 h/12 h light/night cycle. The access of water
and chow was ad libitum. The animals were acclimated
in the animal room during the first week and then di-
vided into eight groups, with eight rats in each group:
Group 1, normal control; Group 2, BPH control; Group
3, DM control; Group 4, BPH +DM; Group 5, EX con-
trol; Group 6, BPH + EX; Group 7, DM + EX; and Group
8, BPH + DM+ EX. The animals were separately caged,
with 2 rats in each cage. In Week 2, DM groups were in-
duced with a single intraperitoneal (ip) injection of
streptozotocin (65 mg/kg) The BPH groups were in-
duced in Week 3 by daily ip injection with Sustanon®
(testosterone, 3.5 mg/head) and estradiol (0.1 mg/head),
consecutively for 8 weeks. Exercise training was con-
ducted from Week 12 until Week 17 on a rat exercise
treadmill (Fortelice, International Co., Ltd., Taiwan). ac-
cording to the program: rats were allowed to sprint at
20 m/min, 60 min per time, three courses per week, this
program was continued successively for a total period of
6 weeks.
Blood collection and analysis of the lipid profiles
The control biochemical data were established at the
end of the first week before experiment. The control
data of the DM-control was established 1 week after
STZ-induction, and those of the BPH-control group was
collected 8 weeks after Sustanon®-induction. Blood collec-
tion was performed at the end of Week 2 and Week 17. In
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Week 17, the rats were bled from the abdominal arteri-
ole immediately before euthanized with CO2 anesthesia.
The blood obtained was centrifuged at 4 °C at 3000 × g
for 10 min using a freezer-type centrifuge (1580 MGR,
Gyrozen, Korea), and the serum high-density lipopro-
tein (HDL), serum low-density lipoprotein (LDL),
serum cholesterol (CHOL), and triglyceride (TG) were
determined using respective kits by following the man-
ufacturer’s instructions.
Collection of tissue specimens
After euthanized, the prostates with seminiferous vesi-
cles and testis were excised, photoed and weighed. Half
of each organ was immersed in a 10 % formalin fixation
solution, and the other half was rapidly immersed into
liquid nitrogen, and stored at −80 °C for further use.
Extraction of proteins
To 200 mg prostate tissues lysis buffer (1.6 mL) was
added, homogenized (microquantity-type homogenizer,
T10 Basic, IKA, Germany) on ice and left to react for
30 min. The homogenate was centrifuged using the
freezer-type centrifuge (1580 MGR) at 12000 × g at 4 °C
for 20 min. The supernatant (protein lysate, PLS) was
separated and stored at −80 °C for further use.
Western blot analysis of 5α-reductase
The PLS was assayed for total protein content. To PSL,
a two-fold volume of Western sample loading dye
(WSLD) solution was loaded. The mixture (named
herein PSL-WSLD) was heated in a dry heating bath
(100 °C) for 10 min, and treated as follows. PSL-WSLD
containing 30 μg of protein was loaded onto 10 % SDS-
PAGE and the electrophoresis was conducted in the
SDS-PAGE electrophoresis chamber (Mini-Protean
Tetra Cell, Bio-Rad, USA), using the SDS-PAGE electro-
phoresis buffer (running buffer of pH 8.3, containing
25 mM Tri-HCl, 192 mM glycine, 0.1 % SDS, and deion-
ized water to adjust to 1 L) at 75 V for 30 min. The pro-
tein spots were electrotransferred onto the PDVF
membrane using a Mini Trans-Blot (Bio-Rad, USA) at
4 °C and 75 V for 20 h. The PVDF membrane was re-
moved and marked with the obtained molecular weight.
The marked membrane was sliced according to the mo-
lecular weight, immersed in a blocking buffer, and agi-
tated at 4 °C overnight. The membrane was rinsed with
a TBST solution thrice and left to stand for 10 min. The
primary antibodies were applied and left to react for 1 h
at ambient temperature, and then rinsed with the TBST
solution. The secondary antibodies were applied, and left
to react at ambient temperature for 1 h. After rinsed with
the TBST solution, enhanced chemiluminescence
(ECL) was applied and left to react completely.
Protein expression was imaged using a luminescent
image analyzer (LAS-4000; Fujifilm, Tokyo, Japan).
Enzyme linked immunosorbent analysis for determining
serum insulin, IGF, TBARS, H2O2, testosterone, DHT and
prostate IL-6
The blood obtained was immediately centrifuged using
the freezer-type centrifuge (1580 MGR) at 3000 × g and
4 °C for 10 min. The supernatant serum was separated
and stored at −80 °C if not used immediately. The sera
were used for determining insulin, IGF, TBARS, H2O2,
testosterone and DHT. Prostatic tissues (100 mg) were
minced into chops having size <3 mm3 and extensively
washed with PBS containing heparin to prevent potential
peripheral blood contamination. The mince was incu-
bated with 200 U/mL type I collagenase and 100 mg/mL
DNase type I (Sigma Chemical Company, St. Louis,
MO) in RPMI 1640 medium plus 10 % fetal calf serum
and 6 % penicillin/streptomycin solution (Gibco BRL
Life Technologies, Gaithersburg). The tissues were disso-
ciated overnight at 37 °C and used for determination of
IL-6. The following protocol for assay was performed
following the instructions given by the manufacturers.
Pathological examination and Sirius Red staining
After CO2-euthanized, prostate, testes, seminal vesicle,
bladder, pancreas, kidneys, heart, liver, and muscles were
excised, photoed and weighed. Half of each organ was
fixed in 10 % formalin, paraffin-embedded, and sliced
with a microtome. The specimens were forwarded to the
National Laboratory Animal Center (NLAC, Taipei) to
receive pathological examination.
The paraffin-embedded specimens were dewaxed with
xylene, and rehydrated successively with gradient etha-
nol solutions (100, 95, 80, and 70 %). These specimens
were first stained with the Fouchet dying agent to attain
a clear contrasting background, then with Weigert’s
haematoxylin to stain the nuclei (to a bluish-black
color), and finally with Sirius Red to stain the collagen
(to red). The semifinished specimens were immediately
dehydrated, mounted, and examined using an optical
microscope (BX41M-ESD, Olympus, Japan).
Immunohistochemical stain for androgen receptor (AR)
and prostatic specific antigen (PSA)
The paraffin-embedded tissue specimens were placed in
an incubator held at 37 °C overnight, immersed in xy-
lene for 10 min to remove the residual embedding paraf-
fin, and successively rehydrated with gradient ethanol
solutions (100, 95, 80, and 70 %). Citric acid (10 mM,
pH 6.0) was added to the rehydrated specimens. After
15 min, the specimens were treated with 3 % H2O2 for
15 min and then rinsed twice with PBS. The primary
antibodies were applied and left to react for 2 h. After
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rinsed twice with PBS, the secondary antibodies were ap-
plied, left to react for 30 min, and peroxidase-conjugated
streptavidin was added to react for 1 h and the speci-
mens were rinsed with PBS twice. Finally, the specimens
were reacted with the coloring agent diaminobenzidine
(DAB) for 30 min, rinsed twice with PBS, dehydrated
with gradient ethanol solutions, and mounted.
Determination of NO
Griess reagent (20 μL) was added to 20 μL of serum (or
tissue homogenate) and mixed well. Double-distilled
water (160 μL) was added to the mixture to make up to
a total volume 200 μL. The optical density was read at
550 nm against the blank. A calibration curve was estab-
lished using 20 μL of a standard sodium nitrite solution,
similarly treated with 20 μL of Griess reagent and
160 μL of double-distilled water, and finally the optical
density was read at 550 nm. The nitric oxide content of
the samples was calculated from the reference curve.
Statistical analysis
Data obtained in the same group were analyzed with
Duncan's multiple range test, using the Statistical Ana-
lysis System software (SAS 9.0). Data were expressed as
mean ± SD. Different letters indicated significant differ-
ences at a confidence level of p < 0.05.
Results
Body weight variation was affected by the treatments
After BPH induction, the body weight of the normal
control and EX control groups steadily increased from
Week 3 until Week 17, reaching 552.5 ± 68.6 g and
557.8 ± 53.4 g, respectively. The body weights of the
BPH and BPH + EX groups increased for the initial
2 weeks until Week 5 to 423.7 ± 53.4 g and 433.0 ±
32.1 g, respectively, and then remained unchanged until
Week 17. In the DM group, a body weight of approxi-
mately 246.0 ± 40.0 g almost remained unchanged all the
way until Week 17. The body weight of the DM+ EX
group increased steadily to 339.5 ± 14.01 g after the EX
intervention. By contrast, the BPH +DM and BPH +
DM+ EX groups rapidly gained weight to 395.7 ± 8.6 g
and 320.0 ± 79.4 g, respectively, in Week 17 (Fig. 1).
Testes weights
Figure 2a-c reveals the testis of BPH, DM, BPH +DM,
DM+ EX, and BPH +DM+ EX were all much smaller in
size compared to the normal. Ex greatly increased the
testes size in BPH group but not in groups DM, BPH +
DM, and BPH +DM+ EX (Fig. 2b, c).
Apparent prostatic size and weight were affected by the
treatments
The mean prostatic weights of the normal control,
EX control, BPH control, BPH + EX, DM control,
DM + EX, BPH + DM, and BPH + DM+ EX groups
were 3.52 ± 0.76 g, 4.03 ± 0.76 g, 4.90 ± 0.65 g, 4.55 ±
0.80 g, 1.38 ± 0.89 g, 2.60 ± 1.09 g, 2.86 ± 0.67 g, and
2.43 ± 1.17 g, respectively (Fig. 3b). Compared with
the normal prostatic size, the EX control exhibited a
slightly enlarged prostate. The morphology and weight
of the prostate in the EX and BPH + EX groups was
comparable (Fig. 3a and b), but a substantial prostatic
weight difference was observed between the normal
and BPH groups (p < 0.05) (Fig. 3b). The prostate in
the DM groups was severely shrunken (Fig. 3a and
b). In the BPH + DM group, the extent of shrinkage
was much less severe than that in the DM group. EX
increased the prostatic size and weight in the DM +
EX group (p < 0.05), but not in the BPH + DM+ EX
group (Fig. 3b).
Lipid profile
The level of HDL for the control, BPH, DM, and
BPH + DM value without EX were 46.8 ± 10.8 mg/dL,
41.7 ± 1.7 mg/dL, 35.4 ± 16 mg/dL, and 38.5 ± 7.6 mg/
dL, respectively. While EX altered the correspond-
ing values to 49.9 ± 13.6 mg/dL, 44.3 ± 6.3 mg/dL,
37.8 ± 11.8.mg/dL, and 43.3 ± 8.9 mg/dL, respectively
(Fig. 4a-b).
Likely, without EX intervention, the serum LDL level
of BPH, DM, and BPH + DM were substantially raised
to 13.4 ± 0.5 mg/dL, 18.2 ± 0.5 mg/dL, and 13.1 ±
1.8 mg/dL, respectively compared to the control 6.8 ±
0.8 mg/dL (Fig. 4a). EX correspondingly alleviated the
values to 8.5 ± 4.4 mg/dL, 13.6 ± 3.3 mg/dL, and 10.6
± 6.1 mg/dL, respectively, comparing with the EX
control 7.3 ± 3.4 mg/dL (Fig. 4b).
Fig. 1 Body weight variation affected by T1DM, BPH, and exercise
intervention. Data are presented as mean ± SD (n =8)
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Moreover, without the EX intervention, the ratio LDL/
HDL revealed to be 0.15, 0.32, 0.51, and 0.34 for groups
normal, BPH, DM, and BPH + DM. As contrast, EX
intervention greatly improved these ratio to 0.15, 0.19,
0.36, and 0.24, respectively.
Without EX intervention, DM and BPH + DM
highly raised the serum TG levels to 200.5 ± 10.1 mg/
dL, and 164.7 ± 9.4 mg/dL compared to the control 61.1
± 9.6 mg/dL (note: The normal gross range is 26–145 mg/
dL) (Fig. 4a). Although BPH had slightly raised this value
to 70.7 ± 7.7 mg/dL, it still fell in normal gross range.
Similarly, without EX intervention DM and DM+ BPH el-
evated the serum CHOL level to 143.8 ± 8.2 mg/dL, and
140.7 ± 15.0 mg/dL. EX intervention slightly suppressed
the CHOL levels in DM and BPH +DM to 138.4 ±
17.4 mg/dL, and 118.3 ± 15.4 mg/dL respectively, while
BPH group showed 57.2 ± 18.1 mg/dL compared to the
EX control 61.3 ± 9.3 mg/dL (Fig. 4b).
Hematoxylin-eosin staining
The prostatic tissues of the BPH group exhibited the
manifestation of epithelial hyperplasia (epithelial cells
piling-up formation)(indicated by solid arrows), as well
as slight interstitial leukocytic infiltration (Fig. 5a and b).
The prostate of DM rats revealed epithelial hyperplasia,
moderate to severe inflammation, moderate lymphocytic
infiltration (indicated by dotted arrows), and slight to
moderately severe acinar atrophy (Fig. 5a and b). In
BPH +DM rats, a high degree of hyperplasia and severe
inflammation were observed. EX alleviated most of these
pathological events (Fig. 4a and b; see BPH + EX, DM +
EX, and BPH +DM+ EX).
Sirius Red staining
Sirius Red stains the collagen to red, in essence
underlying severe collagen deposition with inflammation
of interstitial tissues. In the BPH groups, collagen
Fig. 2 The morphology and size of testis affected by T1DM, BPH, and exercise intervention. Dimensions are indicated by the real length in cm
and inch (a). The left testes weight are indicated as mean ± SD (b). The right testes weight are indicated as mean ± SD (c). The different symbols
in lower case indicate significantly different from each other (p < 0.05). The symbol ‘a’ denotes the highest data, ‘b’ the next, and so on
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deposition substantially increased to 54.32 ± 2.19 %,
which was further enhanced to 333.46 ± 10.35 % in the
DM groups, compared with the normal control value
(10.25 ± 0.28 %). EX substantially reduced the collagen
deposition to 36.37 ± 0.74 % and 308 ± 3.56 % in the
BPH and DM groups, respectively (p < 0.01) (Fig. 5c).
Remarkably, collagen deposition in the BPH +DM
group, whose control exhibited an initial deposition level
of 71.62 ± 2.78 %, was also substantially suppressed by
EX to 37.24 ± 2.20 % (p < 0.05) (Fig. 5c).
Blood glucose levels were affected by BPH, DM, and EX
In Week 17, the mean blood glucose (BG) levels in the
normal, BPH, EX, and BPH + EX groups were 127.0 ±
7.1 mg/dL, 119.7 ± 7.0 mg/dL, 210.5 ± 9.8 mg/dL, and
135.0 ± 12.5 mg/dL, respectively(p < 0.05). In the DM
groups (DM, BPH +DM, DM+ EX, and BPH + DM+
EX), the corresponding values were 600.0 ± 10.1 mg/dL,
594.1 ± 12.0 mg/dL, 525.8 ± 31.7 mg/dL, and 555.4 ±
24.9 mg/dL, respectively (p < 0.01) (Fig. 6a). Thus, DM
prominently increased 4.14–4.72 folds the serum glucose
levels in the DM groups. In the DM+ EX and BPH +
DM groups, the blood sugar levels were substantially,
yet only slightly, decreased (Fig. 6a).
Serum insulin levels in the BPH, DM, and EX groups
The insulin levels in the control and BPH groups were
comparable, ranging from 1.45 ± 0.13 μg/L to 1.68 ±
0.18 μg/L regardless of EX (Fig. 6b). In the DM group
the insulin level was lowered to only 0.62 ± 0.06 μg/L,
which was substantially improved by EX to 0.82 ±
0.05 μg/L (p < 0.05). A similar trend was observed in the
BPH +DM group.
Insulin-like growth factor was affected by BPH, DM,
and EX
The IGF in the normal control was 1087.3 ± 41.0 ng/mL,
EX reduced this level to 535.2 ± 54.9 ng/mL (p < 0.01). In
Fig. 3 Prostatic morphology (a) and prostatic weight (b) affected by T1DM, BPH, and exercise intervention. Dimensions are indicated by the real
length in cm and inch (a). The prostatic weight are indicated as mean ± SD. The different symbols in lower case indicate significantly different
from each other (p < 0.05). The symbol ‘a’ denotes the highest data, ‘b’ the next, and so on
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the BPH, DM, and BPH +DM groups, EX substantially
raised the IGF, compared with each corresponding control
groups (p < 0.05) (Fig. 6c).
Androgen-related biochemical parameters affected by
BPH, DM, and EX
Testosterone
EX considerably increased the serum testosterone levels
to 797.2 ± 89.6 pg/mL, compared with the control value
of 508.6 ± 69.5 pg/mL. BPH increased this concentration
to 972.6 ± 52.4 pg/mL (p < 0.01), whereas EX substan-
tially lowered it to 856.8 ± 55.5 pg/mL (p < 0.05). By con-
trast, the testosterone level was highly suppressed in the
DM control group to 115.5 ± 66.1 pg/mL, and EX re-
stored its level to 543.7 ± 46.6 pg/mL (p < 0.01), being
comparable to that in the normal control. In the BPH +
DM and BPH +DM+ EX groups, the testosterone levels
were increased to 889.3 ± 62.9 pg/mL and 896.1 ±
54.6 pg/mL, respectively (Fig. 7a).
5α-Reductase
In contrast with the testosterone profile, 5α-reductase
exhibited a similar profile in all groups. The relative data
for the normal control, EX control, BPH control, BPH +
EX, DM control, DM+ EX, BPH +DM, and BPH +DM+
EX groups were 0.30 ± 0.07, 0.41 ± 0.12, 0.71 ± 0.05,
0.55 ± 0.04, 0.46 ± 0.10, 0.76 ± 0.07, 0.56 ± 0.07, and
0.76 ± 0.05 folds contrasting to the reference β-actin,
respectively (p < 0.05) (Fig. 7b).
EX upregulated the 5α-reductase levels in the normal
group, although the change was negligible (Fig. 7b).
However, 5α-reductase activity was substantially upregu-
lated in the DM+ EX and BPH +DM+ EX groups. By
contrast, 5α-reductase activity was substantially inhibited
in the BPH + EX group (Fig. 7b).
Dihydrotestosterone
The normal, EX and DM controls exhibited dihydro-
testosterone (DHT) levels of 665.9 ± 37.7 pg/mL,
669.8 ± 76.7 pg/mL, and 122.8 ± 88.4 pg/mL, respect-
ively (p < 0.01). EX did not alter the normal DHT
level, whereas EX substantially raised, yet incom-
pletely restored, the DHT level in the DM group to
351.96 ± 70.34 ng/mL (p < 0.01) (Fig. 7c). Because of
the administration of testosterone (Sustanon®), the
DHT of all BPH groups was raised to levels higher
than those in the normal and DM groups (Fig. 7c).
EX effectively suppressed the DHT levels in the BPH + EX
and BPH +DM+EX groups. Conversely, EX increased
the DHT levels in DM+ EX rats (Fig. 7c).
Androgen receptor and prostate-specific antigen
The androgen receptor (AR) that was once highly
expressed in BPH was substantially suppressed by EX.
By contrast, AR in the DM control appeared to be more
diffusively spreading due to the degenerative destruction
of the tissues (Fig. 7d and e). EX effectively upregulated
AR in the normal and DM groups (p < 0.01), but ap-
parently lowered AR in the BPH and BPH + DM
groups (p < 0.05) (Fig. 7d (×400) and e). In parallel,
the PSA level in the normal control was slightly up-
regulated, and that of BPH and BPH + DM groups
were significantly lowered (Fig. 7f ). Interestingly, the
PSA of DM rats was more apparently localized and
dowregulated by the EX intervention (Fig. 7f )
Pro-inflammatory factors affected by BPH, DM, and EX
Serum hydrogen peroxide
The serum hydrogen peroxide levels were highly stim-
ulated to 17.27 ± 1.19 and 18.34 ± 0.45 μmol/mL re-
spectively in the control groups of DM and BPH +
Fig. 4 The level of serum lipid profile without (a) and with (b)
exercise. The different symbols in lower case indicate significantly
different from each other (p < 0.05). The symbol ‘a’ denotes the
highest data, ‘b’ the next, and so on
Chen et al. BMC Urology  (2015) 15:113 Page 7 of 16
DM compared to the normal 9.88 ± 1.45 and the BPH
control 11.75 ± 0.48 μmol/mL (p < 0.05) (Fig. 7). EX
substantially suppressed the serum hydrogen peroxide
levels to 6.25 ± 0.87, 6.96 ± 0.96, 15.18 ± 0.54, and 9.49 ±
0.68 μmol/mL, respectively for groups normal, BPH, DM,
and BPH +DM (p < 0.05) (Fig. 8).
Serum TBARS
The serum TBARs levels were slightly suppressed in
groups normal and BPH compare to each individual
control. In the DM and BPH + DM controls, the
serum TBARS were highly stimulated to levels 4.54 ±
0.16 μM and 4.7 ± 0.45 μM, respectively (Fig. 9). Al-
though EX completely failed to improve the TBRAs
level in DM group, EX showed slight yet significant
suppressive effect on the TBARS level in the BPH +
DM rats (p < 0.05) (Fig. 9).
Prostate tissue IL-6
The IL-6 levels of each controls were all raised in groups
BPH, DM, and BPH + DM. The levels reached 0.96 ± 0.1,
1.61 ± 0.18, and 2.35 ± 0.17 pg/mL, respectively (Fig. 10).
EX slightly raised the IL-6 level to 0.68 ± 0.04 pg/mL
compared to the normal. Conversely, EX slightly but sig-
nificantly suppressed the IL-6 levels in groups BPH and
DM. Astonishingly, EX effectively alleviated the IL-6
level from 2.4 ± 0.4 pg/mL down to 0.68 ± 0.06 pg/mL in
group BPH +DM (p < 0.01) (Fig. 10).
Fig. 5 Hematoxylin-eosin stain (a), Sirius Red stain (b), and collagen dposition (c) of prostatic tissues affected by different treatments. (in (a) and
(b), magnification: upper × 200, lower panel × 400). Different symbols in lower case in the Fig. 5c indicate significantly different from each other
(p < 0.05). The symbol ‘a’ denotes the highest data, ‘b’ the next, and so on
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Serum nitric oxide
The serum nitric oxide (NO) was upregulated by EX in
all experimental groups, particularly in the BPH group.
The serum NO levels were 175.5 ± 11.2 μM, 243.5 ±
33.1 μM, 132.6 ± 10.5 μM, 357.6 ± 58.7 μM, 135.6 ±
25.0 μM, 248.7 ± 38.4 μM, 137.1 ± 40.0 μM, and 352.3 ±
17.9 μM, respectively for the normal control, EX control,
BPH control, BPH + EX, DM control, DM + EX, BPH +
DM, and BPH +DM+ EX groups (p < 0.05) (Fig. 11).
Discussion
DM severely reduced the prostatic weight, whereas EX
increased that of DM group but not that of BPH + DM
group
Pathologically, BPH is characterized by hyperplastic
epithelial, stromal growth [15] and tissue remodeling in
the aging prostate [16], which was consistent with our
findings (Fig. 5a and b). Stromal-epithelial interaction
plays a critical role in the development and growth of
the prostate gland and BPH [2]. Ikeda et al. indicated
that DM caused a substantial reduction in prostatic
weight and serum testosterone levels in rats [17]. Simi-
lar results were also reported by Porto et al. [18]. The
prostate weight was substantially increased in the BPH
control, compared with the normal control. EX did not
substantially affect the prostatic weight (Fig. 3b). Con-
versely, DM remarkably reduced the prostatic weight,
and EX effectively inhibited the reduction in prostatic
weight (Fig. 3b).
Literature elsewhere also indicated that BPH exhibits
manifestations of hypoxia and chronic inflammation
[19]. We showed that EX slightly improved hyperplasia
and inflammation of the dorsolateral lobe (NLAC report,
not shown here) (Fig. 5a and b), and DM caused epithe-
lial hyperplasia inflammation, lymphocytic infiltration,
and acinar atrophy (NLAC report, not shown here). As
contrast, EX alleviated the chronic inflammation of the
DM+ EX group (Fig. 5a and b).
Here some controversial arguments may arise. One
may claim about the T1DM model to be character-
ized by some important histopathological alterations
that are typical of the initial phase of BPH, including
inflammation, tissue remodeling and increased stro-
mal proliferation and more importantly, which is as-
sociated to a condition of hypogonadism as already
reported by others [20] and pointed out that such a
condition of hypogonadism is also associated with sig-
nificant prostate alterations.
However, there in fact exists a big discrepancy between
the DM model and the BPH model. As cited by Zhang
et al. [20], the DM animal models could be elicited by
two techniques, one by alloxan, and the other by strep-
tozotocin (STZ). Indeed, in the DM model, a state of
hypogonadism would have occurred, and supplement
Fig. 6 Levels of blood glucose (a), insulin (b), and insulin growth
factor (c) affected by T1DM, BPH, and exercise intervention. Data
are expressed as means ± SD. Different symbols in lower case indicate
significantly different from each other . The symbol ‘a’ denotes the
highest data, ‘b’ the next, and so on
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with testosterone definitely would be beneficial [20].
However, we were creating a complicate animal model
that is DM + BPH. DM model was induced at week 2 by
STZ, and the BPH model was then induced one week
later using T + E. Recently, the pathological etiology and
clinical findings for BPH all are pointing to the
Fig. 7 Androgen-related variables affected by T1DM, BPH, and exercise intervention. a Testosterone, b 5α-reductase, c DHT, d AR (upper, ×200;
lower, ×400), e quantitatification of AR, f PSA (magnification, ×200). Data are expressed as mean ± SD (n = 8). Different symbols indicates
statistically different (p < 0.05). The different symbols in lower case indicate significantly different from each other. The symbol ‘a’ denotes the
highest data, ‘b’ the next, and so on
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hypertestosteronemia, dyslipidemia, and oxidative stress.
In our experiment, we really have recognized the change
of testis in different groups involving the DM, BPH and
the DM+ BPH, the testes sizes in DM and BPH were re-
duced slightly, as contrast, EX has apparently recovered
its weight and size (Fig. 2a-c).
Increased body weight and body mass index have been
confirmed to be the risk factors of prostate enlargement
[21–23]. The results presented here are controversial; we
demonstrated that the body weight severely decreased,
suggesting pathological changes in the STZ-induced
DM, testosterone-induced BPH, and innate human DM
models. Previously, we demonstrated that EX was able
to suppress the prostatic inflammation in BPH [7]. A
similar result regarding the DM group was reported by
Belotto et al. [24].
The pathological etiology of dyslipidemia of BPH is
entirely different from DM
In Fig. 4a-b, we showed the dyslipidemic pattern without
and/or with EX intervention in BPH rats was quite dif-
ferent from that of DM and BPH +DM rats. Although
both dyslipidemic profiles were very alike, yet the DM
patients usually show more severe hyperlipidemic mani-
festations than the BPH (Fig. 4a-b). Literature has indi-
cated that metabolic syndrome-associated dyslipidemia
to be the major determinants of prostatic inflamma-
tion [25] and overgrowth [1]. Amazingly, EX seemed
to have further elevated the TG level in BPH to
140.4 ± 17.4 mg/dL, yet still falling within the normal
range (26–145 mg/dL) (Fig. 4b).
According to Nandeesha et al. [26], in human T2DM
the levels, total cholesterol, and LDL-cholesterol were sig-
nificantly higher and HDL-cholesterol was significantly
lower in BPH cases as compared to controls. Hammarsten
et al. also indicated that there was a larger prostate gland
in men with obesity (p < 0.0001), and low HDL-
cholesterol levels (p = 0.0132) than in men without these
conditions [27].
Nonetheless, in this investigation we found these two
types of dyslipidemia in fact were totally different from
each other (Fig. 4a-b), implicating the pathological eti-
ology is completely discrete from each other between
BPH and DM.
EX reduced collagen deposition
BPH is usually implicated in detrusor muscle hyper-
trophy in the early phases of outflow obstruction and
deposition of increasing amounts of extracellular
matrix (e.g., collagen) [24, 28]. Moreover, DM also in-
duces stromal remodeling and a thickening in the
acinar basement membrane of the prostate, accom-
panied by an increase and disorganization of its pro-
teoglycans, chondroitin sulfate, and collagen [29], as
observed in our BPH- and DM-induced models
(Fig. 5c).
The combined effect of DM + BPH + EX is still un-
clear. Previously, we proved EX to alleviate BPH [7]. In
this work, we demonstrated that EX not only apparently
alleviated the hyperplastic epithelial and stromal growth,
inhibiting collagen deposition in BPH (Fig. 5c), but also
reduced the collagen deposition in the DM groups. By
contrast, the literature demonstrated that in DM, EX re-
stores the DM-induced specific ultrastructural changes
in cardiomyopathy, alleviating these symptoms toward
non-DM phenotypes, particularly in the mitochondria
and extracellular matrix proteins [30].
Fig. 8 Levels of serum hydrogen peroxide affected by T1DM, BPH,
and exercise intervention. Different symbols indicates statistically
different (p < 0.05). The different symbols in lower case indicate
significantly different from each other. The symbol ‘a’ denotes the
highest data, ‘b’ the next, and so on
Fig. 9 Levels of serum TBARs affected by T1DM, BPH, and exercise
intervention. Different symbols indicates statistically different
(p < 0.05). The different symbols in lower case indicate significantly
different from each other. The symbol ‘a’ denotes the highest data,
‘b’ the next, and so on
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In the DM and BPH + DM groups, EX substantially
decreased the blood glucose and increased the insulin
levels
Almeida et al. [31] pointed that body adiposity and
glucose homeostasis improved with chronic physical
exercise in Wistar male rat model. In addition, total
insulin content was reduced in group acute trained,
insulin secretion stimulated by glucose was reduced
in trained groups (the aerobic trained and the acute
trained) [31]. According to Almeida et al. [31], a pos-
sible modulating action on insulin secretion is prob-
ably related to the association of chronic adaptation
with an acute response on cholinergic activity in
pancreatic islets. Speculatively, the elevation of IGF
and TG and variation of prostate weight by EX could
be also dependent on such a phenomenon.
Literature has warranted also that blood glucose
concentration is associated with the risk of prostate
enlargement. Diabetic patients were more than twice
as likely to have prostate enlargement compared with
men without DM [13]. Patients with MetS exhibit a
high annual prostate growth rate [21–23]. BPH pa-
tients with MetS exhibit substantially higher serum
glucose levels than do BPH patients without MetS
[32]. In subjects with MetS, the fasting glucose levels
are usually remaining at higher levels than the normal.
Documented data revealed that prostate size correlates
positively with the fasting glucose level (r =0.186, p =
0.007), but not with BMI, testosterone, insulin level, or in-
sulin resistance (each p > 0.05) [30]. Upon multiple
adjusted linear regression analysis, prostate size correlated
with PSA (p < 0.01) and increased fasting glucose
levels (p =0.023) [33]. Worth noting, Kim et al. also
indicated that in non-DM BPH patients with normal
testosterone levels, fasting glucose level is an inde-
pendent risk factor for prostate hyperplasia [33].
In addition, Nandeesha et al. indicated that insulin
level in human was significantly associated with
prostate size, in human BPH cases. And more import-
antly in T2DM patients, insulin has been shown to
be an independent risk factor in the development of
BPH [26].
Previously, Hammarsten et al. had indicated that there
was a larger prostate gland in men with non-insulin-
dependent diabetes mellitus (NIDDM) (p = 0.0058) and
high insulin levels (p < 0.0001) than in men without
these conditions [27].
Taken together, evidently, different animal model
(rats vs. human) and different etiological events
(Type 1 vs Type 2 DM) could reveal different patho-
logical and biochemical outcomes. We showed in this
Type 1 rat model for BPH alone EX did not affect
the insilin level, but in case of BPH + DM, the insulin
level was substantially reduced in the BPH + DM rats,
and EX was seen to slighly ameliorate the insulin
level (Fig. 6b), suggesting that although insulin is an
independent risk factor in the development of BPH,
EX could more or less modulate the pathological
(cholinergic adaptation, [31]) condition associated
with BPH + T1DM (Fig. 6b).
Moreover, EX seemed to have alleviated the testos-
terone level in BPH alone group to reach a level
higher than the normal (Fig. 7a) (which could be due
to the testosterone therapy), while the fasting glucose
levels all maintained at extremely high levels (Fig. 6a),
implicating the risk to aggravate BPH in the T1DM
rats.
Fig. 10 Levels of prostatic IL-6 affected by T1DM, BPH, and exercise
intervention. Different symbols indicates statistically different
(p < 0.05). The different symbols in lower case indicate significantly
different from each other. The symbol ‘a’ denotes the highest data,
‘b’ the next, and so on
Fig. 11 Serum nitric oxide affected by T1DM, BPH, and exercise
intervention. The different symbols in lower case in the figure
indicate significantly different from different groups (p < 0.05). The
symbol ‘a’ denotes the highest data, ‘b’ the next, and so on
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EX upregulated the IGF and alleviated the MetS
The IGF-1, although highly suppressed in the normal
control, was substantially upregulated by EX in the BPH,
DM, and BPH +DM groups (Fig. 6c).
The IGF, another mitogen, and an antiapoptotic agent,
binds to the insulin receptor/IGF receptor, and stimulates
prostate growth [2]. IGFBP-3 seems to be a mulifunctional
protein, which can potentate or inhibit IGF activity [34].
Increased IGF levels and IGF binding proteins (IGFBPs)
in prostate tissue and blood are associated with an in-
creased BPH risk, because they regulate the levels of cir-
culating androgen and growth hormone [2].
Regarding the volume variation of the total prostate
(TP) volume or transitional zone (TZ) volume, literature
has demonstrated that higher PSA (p < 0.001), larger
waist circumference (p < 0.001) and higher IGFBP-3 ex-
pression levels (p = 0.024) are independently associated
with higher TZ volume [34].
The increase of IGF in prostate cancer has been widely
studied. But little has been reported on the possible role
of IGF in BPH [35]. However, reduced modulatory IGF
binding protein levels do seem to be associated with in-
creased BPH risk [35].
Could this be the cause that IGF was decreased in
BPH model (Fig. 6c) compared to the control? We really
still are not very clear about this.
EX alleviated the BPH and BPH + DM by suppressing the
DHT levels, conversely, EX alleviated DM by upregulating
androgens
Recently, we demonstrated that EX alleviated BPH [7].
Biochemically, BPH is considered to be an imbalance be-
tween androgen and estrogen [36], an overexpression of
stromal and epithelial growth factors, cytokines, and
steroid hormones [37, 38]. In the BPH groups, the levels
of testosterone, 5α-reductase, DHT, and AR were all
substantially upregulated (Fig. 7a-e), resulting in sub-
stantially increased PSA levels (Fig. 7f ), a phenomenon
being consistent with the manifestations usually seen in
the clinical treatment of BPH. EX alleviated the BPH
and BPH +DM by suppressing the DHT levels (Fig. 7c).
Subnormal testosterone levels inhibited regular prostate
proliferation and differentiation [39].
The biological significance of enzyme like “5-α-reduc-
tase” definitely is far different from that of the ‘androgen
receptor protein’. 5-α-Reductase is responsible for the
transformation of testosterone into DHT, the latter acti-
vates the translocation of cytosolic AR into the nucleus.
In order to differentiate these two biochemical functions,
we performed the Western blotting of 5-α-reductase
(Fig. 7b), and alternatively, we adopted immunohisto-
chemical (IHC) stain to examine the nuclear transloca-
tion of AR (Fig. 7d).
At this stage, we purposely utilized the IHC stain to
observe the AR with the goal not only aiming at its
quantities, but also its in vivo distribution site. As can be
expected, after homogenized the cytosolic and the nu-
clear AR’s would be homogeneously mixed together, and
at this stage, even though you could identify a tremen-
dous amount of AR by Western blot, you still could not
differentiate the activated AR and its localization into
nuclei. On the other hand, we skipped the ER, because
ER in reality is not involved in such a biochemical trans-
formation and translocation mechanism.
In the DM group, AR was substantially downregulated
(Fig. 6d and e), which was in agreement with Gorba-
chinsky and Liu and Wang [33, 40]. Literature indicated
that the prostatic cytosolic AR content was negatively
correlated with the plasma glucose levels [41]. We
showed EX alleviated DM by upregulating androgens
and AR (Fig. 7d), and EX increased the testosterone
levels in the DM+ EX group (Fig. 7a)
EX alters the sex hormones and their receptors associ-
ated with the balance between apoptosis and cell prolif-
eration in the ventral prostate [41]. EX increased the
plasma corticosteroid, DHT, and testosterone levels in
the DM groups (Fig. 7a-c), and possibly via these mech-
anism prevented the apoptosis of glandular epithelium
[42] and protected the prostate from MetS-induced
prostate hypoxia, fibrosis, and inflammation [43].
The manifestations exhibited by the BPH +DM groups
could become even more complicated. No substantial
differences in the testosterone levels between the BPH +
DM control and the BPH +DM+ EX were observed. To
compare, the 5α-reductase was upregulated in BPH +
DM (Fig. 6b), while the level of DHT was downregulated
(Fig. 7c), which implicates the lowering of PSA as shown
in Fig. 5f. As contrast, in the BPH group only, EX down-
regulated 5α-reductase (Fig. 7b) and consequently, DHT
was substantially downregulated (Fig. 6c), leading to the
lowering of PSA level (Fig. 7f ).
Interestingly, EX seemed to exhibit a biphasic action
model between BPH and DM. In the BPH only, EX sup-
pressed the serum level of testosterone, 5α-reductase
and DHT (Fig. 7a-c). In the DM patients EX elevated T,
5α-reductase and DHT (Fig. 7a-c). While in BPH +DM,
although EX stimulated the activity of 5α-reductase,
however EX suppressed the DHT without affecting the
testosterone level (Fig. 7a-c).
As well known, high zinc level tends to inhibit the ac-
tivity of 5α-reductase [44]. The middle socioeconomic
DM patients exhibited lower serum zinc levels (1.05–
4.8 mg/dL in males and 1.7–3.5 mg/mL in females) than
the normal non-diabetic population [45]. As contrast, no
significant decrease in plasma zinc between BPH and
normal controls [46]. Thus in the BPH patients, the pro-
duction of DHT via the action of 5α-reductase could be
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merely via the plasma substrate testosterone level con-
trolled kinetics (Fig. 7a-c). Nonetheless, in BPH compli-
cated with DM, the plasma zinc level may play a very
important role [45]. As seen, the activity of 5α-reductase
was de-repressed in the DM and BPH +DM controls
compared to the normal subjects (Fig. 7b). Furthermore,
EX tends to accelerate sweating rate. Some endurance
runners had significantly lower serum zinc concentra-
tions (<11.5 μmol/L) than did men who were not partici-
pating in chronic exercise [47]. Such tremendous zinc
loss by sweating could cause further lowering of serum
zinc level, resulting in highly de-repressed 5α-reductase
(Fig. 7b, c).
EX effectively alleviated the oxidative stress in BPH + DM
by suppressing the serum TBARS and H2O2
TBARS level was significantly increased in type 2 DM
with the duration of disease and development of compli-
cations [48]. Similarly we showed the serum TBARs level
was highly raised in both the T1DM and the BPH +DM
rats (Fig. 9). MetS raised the oxidative stress expressed
as H2O2 and MDA despite in T1DM or T2DM [49].
BPH is always associated with oxidative stress [50]. DM
more severely raised the serum TBARs and H2O2 levels
(Figs. 8, 9). We demonstrated that EX ineffectively sup-
pressed the serum TBARs level in T1DM (Fig. 9). Con-
sistent with this, Laaksonen and Sen reported that the
increased plasma TBARS in the diabetic men both at
rest and after exercise [51]. As contrast, EX effectively
suppressed the serum TBARs level in the BPH +DM
when compared to the BPH +DM control (Fig. 9). To
compare, EX effectively inhibited the production of
serum H2O2 levels in both the DM and BPH +DM
groups (Fig. 8). The strongly negative association be-
tween plasma TBARS and VO2 max suggests that good
physical fitness may have a protective role against oxida-
tive stress [52]. Results implicated that the oxidative
stress associated with DM was more likely related to the
lipid peroxidation, whereas that in BPH was more likely
due to the elevation of serum H2O2 level.
EX effectively alleviated the inflammation in BPH + DM by
suppressing the prostate IL-6
Although in BPH, interleukin-6 (IL-6) was localized pre-
dominantly in basal cells of epithelia, IL-6 receptor was
expressed in benign prostatic tissue in both epithelial
and stromal cells [51], no IL-6 expression was detected
in stromal cells on immunohistochemistry [53]. IL-6 is a
pleiotropic cytokine that interacts with its receptor in
prostate cells, thus regulating proliferative response and
differentiation in prostates. The consequences of in-
creased IL-6 expression could play a role as a mediator
of acute phase reaction and as a pleiotrophic cytokine
influencing antigen specific immune responses and
inflammation, as well as a growth factor for prostate epi-
thelial cells [54]. We showed prostatic IL-6 was raised in
BPH control, while EX only slightly yet significantly sup-
pressed its level (Fig. 10). as contrast, IL-6 was substan-
tially raised in the DM and BPH +DM controls, in these
two groups EX was seen effectively suppressed the eleva-
tion of IL-6. In particular, the level of IL-6 in BPH +DM
was effectively alleviated to a level as that of control,
underlying the promising effect of EX for amelioration
of the inflammatory manifestation of BPH +DM, but to
a lesser extent for the DM.
Considerable production of NO ameliorated BPH, DM, and
BPH + DM
EX highly stimulated the serum NO production (Fig. 11).
Pathologically speaking, BPH is always characterized by
hypoxia and chronic inflammation [19]. NO plays a cru-
cial role in the autonomic innervations of all compart-
ments of prostatic tissues. In obstructive BPH, the
nitrinergic innervation is reduced compared to that in a
normal prostate tissue [55], resulting in an enhancement
of vasodilatation and blood flow, a promising strategy
for treating BPH.
To date, interest in the NO pathway as a potential
pharmacological target to treat male LUTS is increasing.
Thus, given a potential role of the NO-pathway in the
prostate and LUT, enhancing NO production can be a
promising strategy to control the smooth muscle func-
tion in the human prostate [56].
To emphasize, metabolic syndrome (MetS) is a com-
plex, highly prevalent disorder and a worldwide epi-
demic. In T2DM, central obesity, insulin resistance,
dyslipidemia, and hypertension are the main compo-
nents of MetS [57]. As contrast, T1DM is insulin-
dependent. In our experiment, Streptozotocin induces
insulitis and subsequent degeneration of the Langerhans
islets beta cells, so the model was a mimic of diabetes
type 1 as evidenced by the lowered level of insulin,
which in fact was very similarly to the patients affected
by DM type 1. While DM type 2 patients, as conse-
quence of insulin resistance, usually show normal or
higher level of insulin. Consequently our findings have
elicited limitations to the extension of these biochemical
findings in a human setting of patients, mostly affected
by DM type 2.
Despite T2DM our T1DM, there is growing evidence
of the association of MetS with the initiation and clinical
progression of BPH and PCa, molecular mechanisms
and effects on treatment efficacy remain unclear [57].
Conclusion
EX can alleviate BPH, DM, and BPH +DM. EX provokes
androgen remodeling and the specific expression of NO
which may play an essential role in enhancing the effect
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of EX. Data from the peer-reviewed literature suggest an
association of MetS with BPH and Pca in humans, al-
though the evidence for a causal relationship remains
missing. MetS, including TDM and T2DM, should be
considered a new domain in basic and clinical research
in patients with prostatic disorders. Further research is
required to better understand the role of MetS in BPH
and PCa. Even so, clinical urologists need to be
cognizant of the effect that MetS has on urologic dis-
eases, as well as on overall patient health. It is of certain
that this model in reality has raised some unexpected re-
sults that could be haphazard and the consequence due
to the small sample size and the complicate model ra-
ther than a real biological effect of BPH and/or DM
and/or EX. Hence a further research is required to better
understand the effects of EX on the oxidative inflamma-
tory pathway.
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